What ChondroFiller injection costs in the UK

The cost of a ChondroFiller injection in the UK follows a fixed, three-tier structure based solely on how many boxes of the collagen scaffold are required — not on which joint is being treated or where in the country the clinic is located.

| Boxes required | Guide cost | |---|---| | One box | £3,000 | | Two boxes | £5,500 | | Three boxes | £8,000 |

These figures are published by London Cartilage Clinic and used as guide costs across UK providers. The same schedule applies to the hip joint as to any other joint — there is no hip-specific surcharge within the model itself.

All three price points are all-inclusive. A well-structured quote covers the pre-procedure consultation, imaging review, real-time ultrasound guidance on the day, the ChondroFiller implant (the dominant cost component), IV antibiotic cover, and a six-week follow-up appointment — with no separately billed extras on the day.

The majority of focal hip cartilage defects are treated with one box, placing most patients at approximately £3,000. Larger or multi-compartment hip defects may require two or three boxes, and some providers cite a broader approximate range of £6,500–£9,500 for the hip on this basis — reflecting the joint's surface area rather than a different pricing model. That broader figure is less consistently published across sources than the standard three-tier schedule.

Critically, the box count is determined before the day of the injection, at the pre-procedure MRI or imaging review, so patients know their exact total cost before committing to treatment. There is no open-ended bill.

Why ChondroFiller injection costs more than a standard hip injection

Understanding the price gap starts with regulatory classification. ChondroFiller is a CE-marked Class III medical device — the same regulatory tier as a hip implant or cardiac stent — meaning it has been assessed as having an active, sustained biological role inside the body. Corticosteroid and hyaluronic acid injections sit in a lower category: they are pharmaceutical products that manage symptoms. ChondroFiller is not.

The implant is manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. It is not an off-the-shelf clinic consumable that can be bought in bulk; each box must be sourced, cold-chain managed, and administered within a regulated clinical framework.

The mechanism also differs fundamentally from a lubricant or anti-inflammatory injection. Once placed in the hip joint, ChondroFiller gels in situ and chemotactically recruits the patient's own progenitor cells — a process called matrix-induced chondrogenesis — providing a structural scaffold for endogenous cartilage repair rather than temporary symptom relief.

The cost premium reflects these three factors: the implant itself, the Class III regulatory pathway, and the supply chain involved in importing a prescription medical device. It is more usefully compared to other Class III implant procedures than to a routine injection clinic appointment.

ChondroFiller and the NHS — why it is a private-only procedure

No NHS route exists for ChondroFiller injection — for the hip or any other joint. It sits entirely outside NHS commissioning across all regions of England, including Lincolnshire. Patients seeking this treatment must self-fund or obtain approval from a private insurer; there is no GP referral pathway that leads to it on the NHS.

This is a commissioning gap, not a clinical prohibition. ChondroFiller holds CE-marking as a Class III medical device and carries an established safety record across more than 19,000 cases globally. Its absence from NHS funding reflects how NHS England prioritises and commissions procedures — not any regulatory concern about the device itself.

The NHS does commission cartilage repair — but in a very different form. Autologous Chondrocyte Implantation (ACI) received NICE approval in 2017 and is available at a small number of specialist centres in England, including University Hospital Southampton. ACI involves two separate surgical stages: a biopsy to harvest cartilage cells, followed by a second operation to implant the cultured cells back into the joint. Crucially, NHS commissioning of ACI is focused on the knee, not the hip — meaning patients with focal hip cartilage defects face a further gap even within the NHS's existing cartilage-repair provision.

For hip cartilage patients in Lincolnshire and across the wider non-London catchment, ChondroFiller injection is therefore a private pathway by necessity rather than by preference.

Private health insurance and ChondroFiller for the hip

Private cover is not routine for ChondroFiller injection — but it is not impossible, and the steps for exploring it are straightforward.

ChondroFiller procedures are billed under two recognised CCSD medical codes: W3111 (cartilage regeneration with collagen scaffold) and W8500. Because these are established procedural codes, the claim is legible to UK private insurers rather than appearing as an unlisted or experimental item. Case-by-case approvals have been reported from insurers including Bupa, Aviva, and WPA — these are illustrative examples of where approvals have occurred, not an indication that any of those providers cover this treatment automatically or routinely.

Before approaching an insurer, it is worth asking two distinct questions: whether the procedure itself falls within the policy, and — separately — whether the implant cost is included. Some insurers have approved the procedural element while excluding the cost of the ChondroFiller device, which is the dominant cost component in the overall fee.

Written pre-authorisation must be obtained before any appointment is booked. A verbal indication of interest from a case manager does not constitute approval. Insurer policies on medical devices can change, and each patient's position should be confirmed directly with their provider before proceeding.

How ChondroFiller injection works for hip cartilage defects

Delivering ChondroFiller to the hip joint does not involve an operating theatre. The entire pathway takes place as an outpatient appointment: real-time ultrasound guidance is used to position the needle precisely within the hip joint, the injectable collagen scaffold is placed, and the patient goes home the same day. From arrival to discharge, the appointment typically runs 30 to 45 minutes, with no general anaesthetic and no surgical incision.

This is a meaningful practical difference from arthroscopic hip cartilage procedures, which require theatre time, anaesthesia, and a recovery period measured in weeks. ChondroFiller injection sits at a different point on the hip treatment pathway — minimally invasive and day-case by design.

Who is suitable

Patient selection is important. ChondroFiller injection targets focal hip cartilage defects — typically Grade III or IV lesions with healthy cartilage borders surrounding the damage. Lesion size guidance from the clinical evidence base supports defects up to approximately 3 cm², extendable to around 6 cm² where additional product is used. The scaffold works by providing a matrix that recruits the patient's own progenitor cells — a process described as matrix-induced chondrogenesis — rather than delivering cells directly.

Advanced, diffuse hip osteoarthritis (Tönnis grade 2–3) is not an indication. ChondroFiller injection is a joint-preservation option for suitable focal defects; it is not a substitute for hip replacement in patients with end-stage disease.

What the evidence shows

Across published clinical data covering knee, hip, and small-joint applications, some 70–85% of treated patients achieve meaningful symptom relief at three to five years of follow-up. Hip-specific outcome data from UK centres is not separately published in the public domain, so this figure should be understood as spanning joint types rather than being derived from a hip-only cohort.

Getting a ChondroFiller injection for the hip in Lincolnshire

For patients in Lincolnshire and the wider non-London catchment, access to ChondroFiller injection for the hip does not require a journey to London. AMSK Clinic holds clinical presence in both the capital and Lincolnshire, with local access points including Sleaford and Grantham.

The pathway begins with a clinical consultation and MRI imaging review to confirm suitability and establish the box count — and therefore the total cost — before any commitment is made. No GP referral is needed at any stage.

Professor Paul Y. F. Lee, who leads this treatment within the MSK Doctors group, holds an Honorary Professorship at the University of Lincoln — a direct regional academic connection that reflects the clinical presence in this area rather than a purely metropolitan service.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.